UNSPSC 51381907: Oxolamine citrate

This classification denotes an antitussive agent with the molecular formula C14H19N3O.C6H8O7, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5X4XBR694, chemically known as 1,2,4-oxadiazole, 5-(2-(diethylamino)ethyl)-3-phenyl-, citrate but more generally known as oxolamine citrate, which bears US NIH Compound Identifier 16045. European Medicines Agency schedules Oxolamine citrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03576MIG.

Most nations, for tariff and trade purposes, schedule oxolamine citrate under HS 29349990 and SITC 51579. As of Q4 2014, OXOLAMINE CITRATE remains US FDA's Preferred Term for this commodity. SMILES: CCN(CC)CCC1NC(NO1)C2CCCCC2.C(C(=O)O)C(CC(=O)O)(C(=O)O)O.

UNSPSC 51381907 Oxolamine citrate is a Commodity code that covers pharmaceutical products state and local governments procure for health and community health programs. Recent solicitations reveal that state and local buyers are acquiring naloxone, over-the-counter medications, and generic pharmaceuticals through both direct procurement and cooperative purchasing arrangements. The buying mix spans county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Issuing bodies range from individual counties undertaking standalone competitive bids to state-level cooperative purchasing organizations coordinating procurement across multiple jurisdictions.

Activity is concentrated in Florida and the upper Midwest. Seminole County, Florida released an IFB (Solicitation IFB60459723LAS) on June 30, 2026, with a response deadline of July 26, 2023, to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013) in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling forward movement toward formal pharmacy contracting. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal (S1070000015802) on January 20, 2026, with a March 26, 2026 response deadline, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities in Minnesota and Oregon. Vendors responding to cooperative purchasing vehicles must maintain relationships with authorized wholesalers, comply with cGMP and FDA requirements, and accept administrative fees typically in the 3 percent range.